Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New registry tracks lazy eye treatment in real life

NCT ID NCT06429280

Knowledge-focused Sponsor: Luminopia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will collect data from 500 people with amblyopia (lazy eye) who are using Luminopia, an FDA-approved software treatment that works by showing different images to each eye. Researchers want to see how vision changes over time, how well patients stick with the treatment, and whether improvements last after stopping. The goal is to learn how this novel therapy performs in real-world clinics.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Luminopia (therapeutic software delivered via a medical device)
What this could lead to
If successful, this registry could provide real-world evidence on how well Luminopia works for amblyopia in everyday practice, helping doctors refine treatment approaches.
What could go wrong
This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by patient selection or incomplete data.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with a diagnosis of Amblyopia

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of amblyopia * Have undergone or currently undergoing Luminopia treatment for a minimum of 12 weeks Exclusion Criteria: -Have participated in prior Luminopia clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amblyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amblyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amblyopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    13 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Children's Eye Institute of Savannah

    RECRUITING

    Savannah, Georgia, 31406, United States

  • Children's Hospital Of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • Concord Eye Center

    RECRUITING

    Concord, New Hampshire, 03301, United States

  • Eye Physicians of Central Florida

    RECRUITING

    Maitland, Florida, 32751, United States

  • Family Focus Eye Care

    RECRUITING

    Gainsville, Florida, 32605, United States

  • Honolulu Eye Clinic

    RECRUITING

    Honolulu, Hawaii, 96813, United States

  • Lurie Children's Hospital

    RECRUITING

    Chicago, Illinois, 60611, United States

  • Nevada Eye Physicians

    RECRUITING

    Las Vegas, Nevada, 89149, United States

  • Okaloosa Ophthalmology

    RECRUITING

    Crestview, Florida, 32536, United States

  • Pediatric Eye Specialist

    RECRUITING

    Fort Worth, Texas, 76104, United States

  • Riley Children's Hospital at IU Health

    RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Sansum Clinic

    RECRUITING

    Santa Barbara, California, 93110, United States

  • UCSF Benioff Children's Physicians

    RECRUITING

    San Ramon, California, 94583, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.